Chimera is re-programming the software of the immune system to kick cancer to the curb.

Chimera Bioengineering is a biotherapeutics company building RNA based gene regulatory systems for chimeric antigen receptor CAR-T cell therapeutics with greater efficacy against solid tumors.

By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CAR-Ts) are reprogrammed immune cells hot-wired to circumvent immune-evasion. CAR-Ts against leukemias and lymphomas have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities and limited persistence are impediments to these therapies making a wider impact on cancer patients.

Chimera Bioengineering solves the challenges of CAR-Ts with RNA-based gene regulatory systems which allow us to re-program the "software" of the immune system. We design CAR-T behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CAR-T therapy can lead to cures.

Chimera is a spin-out of Christina Smolke’s lab at Stanford University, where she is a Professor of Bioengineering.

To learn more about Chimera’s approach to ending cancer, visit: https://www.chimera.bio/.

To learn more about Chimera co-founder Dr. Smolke, visit: the https://www.linkedin.com/in/christina-smolke-87a8b3b6/.